Angiotensin-converting enzyme 2: a double-edged sword in COVID-19 patients with an increased risk of heart failure - Razeghian-Jahromi, Iman; Zibaeenezhad, Mohammad Javad; Lu, Zhibing; Zahra, Elyaspour; Mahboobeh, Razmkhah; Lionetti, Vicenzo (Heart failure reviews, 2021)
Keywords: ACE2; Angiotensin II; Angiotensin-converting enzyme 2; Angiotensin-Converting Enzyme 2 - antagonists & inhibitors; Angiotensin-Converting Enzyme 2 - physiology; Angiotensin-converting enzyme inhibitors; Angiotensin-Converting Enzyme Inhibitors - adverse effects; Angiotensin-Converting Enzyme Inhibitors - pharmacology; Angiotensin-Converting Enzyme Inhibitors - therapeutic use; Cardiology; Cardiovascular diseases; Cell surface; Clinical trials; Congestive heart failure; Coronary artery disease; Coronaviruses; COVID-19; COVID-19 - chemically induced; COVID-19 - epidemiology; Diuretics; Enzymes; Heart failure; Heart Failure - drug therapy; Humans; Medicine; Medicine & Public Health; Morbidity; Muscle contraction; Pandemics; Peptidyl-dipeptidase A; Public health; Renin; Renin-Angiotensin System - drug effects; Renin-Angiotensin System - physiology; Risk Assessment; Severe acute respiratory syndrome coronavirus 2; Therapeutic targets; COVID-19; Heart failure; ACE2; SARS-CoV-2; RAS inhibitors; Angiotensin II